Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1186/s13054-020-03166-0 http://scihub22266oqcxt.onion/10.1186/s13054-020-03166-0 32682440!7411343!32682440     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=32682440&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       Crit+Care 2020 ; 24 (1): 445 Nephropedia Template TP {{tp|p=32682440|t=2020. Blocking IL-1 to prevent respiratory failure in COVID-19 |pdf=|usr=}}{{32682440}} gab.com Text Blocking IL-1 to prevent respiratory failure in COVID-19 JO: Crit Care http://www.kidney.de/pget.php?&tw=1&pmid=32682440 #FOAvip COVID-19 is an emerging disease that can manifest itself as asymptomatic or mild respiratory tract infection in the majority of individuals, but in some, it can progress into severe pneumonia and acute respiratory distress syndrome (ARDS). Inflammation is known to play a crucial role in the pathogenesis of severe infections and ARDS and evidence is emerging that the IL-1/IL-6 pathway is highly upregulated in patients with severe disease. These findings open new avenues for host-directed therapies in patients with symptomatic SARS-CoV-2 infection and might in addition to antiviral treatment be enough to curb the currently unacceptably high morbidity and mortality associated with COVID-19. Twit Text FOAVip Blocking IL-1 to prevent respiratory failure in COVID-19 ????Crit Care http://www.kidney.de/pget.php?&tw=1&pmid=32682440 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32682440 #FOAvip English Wikipedia <ref>{{Cite pmid|32682440}}</ref> Blocking IL-1 to prevent respiratory failure in COVID-19 #MMPMID32682440 van de Veerdonk FL; Netea MG Crit Care 2020[Jul]; 24 (1): 445 PMID32682440show ga COVID-19 is an emerging disease that can manifest itself as asymptomatic or mild respiratory tract infection in the majority of individuals, but in some, it can progress into severe pneumonia and acute respiratory distress syndrome (ARDS). Inflammation is known to play a crucial role in the pathogenesis of severe infections and ARDS and evidence is emerging that the IL-1/IL-6 pathway is highly upregulated in patients with severe disease. These findings open new avenues for host-directed therapies in patients with symptomatic SARS-CoV-2 infection and might in addition to antiviral treatment be enough to curb the currently unacceptably high morbidity and mortality associated with COVID-19. |COVID-19[MESH] |Coronavirus Infections/complications/*drug therapy[MESH] |Humans[MESH] |Interleukin 1 Receptor Antagonist Protein/therapeutic use[MESH] |Interleukin-1/*antagonists & inhibitors[MESH] |Pandemics[MESH] |Pneumonia, Viral/complications/*drug therapy[MESH]Blocking IL-1 to prevent respiratory failure in COVID-19 (epmc).pdf DeepDyve Pubget Overpricing